Drug Week articles from November 2002

Drug Week archives from November 2002

Antipsychotic drug has few side effects.
November 1, 2002... 2002 NOV 1 - (NewsRx.com & NewsRx.net) -- A drug used to help control psychotic behavior in people with schizophrenia holds promise for controlling similar symptoms in the early stages of Alzheimer disease, a new study suggests. What sets...

AI designed for telecommunications will speed drug development.
November 1, 2002... 2002 NOV 1 - (NewsRx.com & NewsRx.net) -- At this year's Quantitative Structure-Activity Relationships (euro QSAR) symposium, where the pharmaceutical industry discusses drug design, BTexact Technologies, BT's advanced research and technology...

New drug may help recovering cocaine addicts.
November 1, 2002... 2002 NOV 1 - (NewsRx.com & NewsRx.net) -- Nocaine, a new drug developed through Georgetown University Medical Center's Drug Discovery Program may help cocaine addicts withdraw from their habit in much the same way that methadone helps heroin...

FDA approves Avapro (irbesartan) to slow kidney disease.
November 1, 2002... 2002 NOV 1 - (NewsRx.com & NewsRx.net) -- Bristol-Myers Squibb Co. (BMY) and Sanofi-Synthelabo (SNY) announced that the U.S. Food and Drug Administration (FDA) has approved Avapro (irbesartan) for a new indication: the treatment of diabetic...

Research predicts therapies most likely to work.
November 1, 2002... 2002 NOV 1 - (NewsRx.com & NewsRx.net) -- New research findings by scientists in Germany - soon to be published in the Royal Society's Proceedings B journal ("From HIV infection to AIDS: A dynamically induced percolation transition") - will be...

Novel agent effective against cytomegalovirus shedding.
November 1, 2002... 2002 NOV 1 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Researchers in the United States and Europe say that a novel agent can safely reduce cytomegalovirus shedding in HIV+ men. "1263W94 [maribavir;...

Positive phase I results reported with intranasal morphine.
November 1, 2002... 2002 NOV 1 - (NewsRx.com & NewsRx.net) -- Innovative Drug Delivery Systems, Inc., (IDDS) announces results of a phase I clinical trial of its proprietary formulation of Intranasal Morphine that assessed the safety, tolerability and...

Phase II clinical trial of AGIX-4207 initiated.
November 1, 2002... 2002 NOV 1 - (NewsRx.com & NewsRx.net) -- AtheroGenics, Inc., (AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, has announced the initiation of a phase II clinical trial of AGIX-4207 for the treatment...

Solarase marketing agreement announced by SkyePharma and Meditech.
November 1, 2002... 2002 NOV 1 - (NewsRx.com & NewsRx.net) -- SkyePharma, PLC, (SKYE) and Meditech Research, Ltd., announced a reciprocal licensing agreement concerning Solarase, a topical therapy for the precancerous skin condition, actinic, or solar, keratosis,...

Itraconazole reduces amphotericin B efficacy against pulmonary aspergillosis.
November 1, 2002... 2002 NOV 1 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - A pair of commonly used antifungal agents should not be combined when treating patients with pulmonary aspergillosis, researchers in the United States warn. ...

Developer of HDL therapies begins second clinical study of RLT peptide (ETC-642).
November 1, 2002... 2002 NOV 1 - (NewsRx.com & NewsRx.net) -- Esperion Therapeutics, Inc., (ESPR), a biopharmaceutical company focused on discovering and developing HDL-targeted therapies, announced the initiation of a second phase I clinical study of its RLT...

E.C. approves MAA for recombinant protein treatment for tibia fractures.
November 1, 2002... 2002 NOV 1 - (NewsRx.com & NewsRx.net) -- Wyeth (WYE) and Yamanouchi Europe, B.V., the European organization of Yamanouchi Pharmaceutical Co., Ltd., announced that the European Commission has approved a marketing authorization application (MAA)...

Phase I/II study of RSR13 initiated.
November 1, 2002... 2002 NOV 1 - (NewsRx.com & NewsRx.net) -- Allos Therapeutics, Inc., (ALTH) announced the initiation of a phase I/II clinical trial of RSR13 (efaproxiral) for patients with locally advanced cancer of the cervix receiving chemoradiation. ...

Preclinical efficacy studies: Antex STD vaccine protects against infection.
November 1, 2002... 2002 NOV 1 - (NewsRx.com & NewsRx.net) -- Antex Biologics, Inc., (ANX) announced that its Tracvax vaccine against Chlamydia trachomatis, the world's most prevalent sexually transmitted disease, provides protection against infection in...

Results of small photodynamic therapy study reported.
November 1, 2002... 2002 NOV 1 - (NewsRx.com & NewsRx.net) -- Data from the first year of a small study of photodynamic therapy with verteporfin for subfoveal choroidal neovascularization (CNV) secondary to the ocular histoplasmosis syndrome (OHS) have been...

InnaPhase signs technology agreement.
November 1, 2002... 2002 NOV 1 - (NewsRx.com & NewsRx.net) -- InnaPhase Corporation, a leading provider of enterprise technology solutions for life sciences, recently announced that SGS BioPharma, a leading contract research organization, has signed a license...

Sicor wins ANDA approval for propofol injection emulsion 10 mL.
November 1, 2002... 2002 NOV 1 - (NewsRx.com & NewsRx.net) -- Sicor, Inc., (SCRI) announced that its wholly owned subsidiary, Gensia Sicor Pharmaceuticals, Inc., has received approval of an abbreviated new drug application (ANDA) from the U.S. Food and Drug...

Patients with type 2 diabetes find walking easier after sulodexide treatment.
November 1, 2002... 2002 NOV 1 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - Sulodexide treatment improved the walking ability of type 2 diabetic patients with peripheral arterial obstructive disease, according to a report in...

ACAAI: Sedating antihistamine may double risk of serious injury.
November 1, 2002... 2002 NOV 1 - (NewsRx.com & NewsRx.net) -- A commonly used sedating antihistamine available over-the-counter (OTC) was found to have twice the risk of causing serious personal injury compared with a nonsedating antihistamine in a new study...

New report examines drug delivery technologies.
November 1, 2002... 2002 NOV 1 - (NewsRx.com & NewsRx.net) -- Jain PharmaBiotech announced the release of the new report titled "Transdermal Drug Delivery - technologies, markets, and companies". Various transdermal drug delivery technologies are described...

New patent granted for Niaspan-based cholesterol products.
November 1, 2002... 2002 NOV 1 - (NewsRx.com & NewsRx.net) -- Kos Pharmaceuticals, Inc., (KOSP) announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 6,406,715 entitled "Intermediate Release Nicotinic Acid Compositions for Treating...

Pregabalin may not save epilepsy drug market from generic erosion.
November 1, 2002... 2002 NOV 1 - (NewsRx.com & NewsRx.net) -- Decision Resources, Inc., a research and advisory firm focusing on pharmaceutical and healthcare issues, announced that Pfizer's pregabalin may not be enough to save the epilepsy drug market from...

U.S. issues two patents to protect chlorotoxin.
November 1, 2002... 2002 NOV 1 - (NewsRx.com & NewsRx.net) -- TransMolecular, Inc., announced the issuance of two new patents that permit the company - a Birmingham-based neuroscience biotechnology company - to retain all rights to chlorotoxin and its use in...

Enrollment for Symlin dose titration study completed.
November 1, 2002... 2002 NOV 1 - (NewsRx.com & NewsRx.net) -- Amylin Pharmaceuticals, Inc., (AMLN) announced the completion of enrollment of a dose titration study of Symlin (pramlintide acetate) in patients with type 1 diabetes who are actively trying to improve...

FDA issues nonapprovable letter for Helicide.
November 1, 2002... 2002 NOV 1 - (NewsRx.com & NewsRx.net) -- Axcan Pharma, Inc., announced that the U.S Food and Drug Administration has determined that the New Drug Application (NDA) that Axcan submitted for Helicide in the eradication of Helicobacter pylori, is...

FDA approves Hepsera for treatment of chronic hepatitis B.
November 1, 2002... 2002 NOV 1 - (NewsRx.com & NewsRx.net) -- Gilead Sciences (GILD) announced that it received U.S. Food and Drug Administration (FDA) approval for its antiviral agent Hepsera (adefovir dipivoxil) for the treatment of chronic hepatitis B. ...

Clinical trials initiated to explore use of adalimumab.
November 1, 2002... 2002 NOV 1 - (NewsRx.com & NewsRx.net) -- Abbott Laboratories (ABT) announced the expansion of its immunology clinical trials program to include studies evaluating the potential of the first fully human monoclonal antibody, D2E7 (adalimumab),...

Manufacturing process of Eprex in question.
November 1, 2002... 2002 NOV 1 - (NewsRx.com & NewsRx.net) -- A lawsuit seeking class action status has been filed in the United States District Court for the District of New Jersey on behalf of all those who purchased or otherwise acquired the publicly traded...

Web site provides patient eligibility information for clinical trials.
November 1, 2002... 2002 NOV 1 - (NewsRx.com & NewsRx.net) -- ILEX Oncology, Inc., (ILXO) has announced the launch of www.clofarex.com. Clofarex (clofarabine), a second-generation nucleoside analogue, is currently being studied as a potential treatment for...

Enrollment for study of Alvimopan completed.
November 1, 2002... 2002 NOV 1 - (NewsRx.com & NewsRx.net) -- Adolor Corporation (ADLR) announced completion of enrollment in the first phase III clinical trial (OBD 304) for use of its product candidate, alvimopan, in managing opioid induced bowel dysfunction....

IND filed for buccal fentanyl with Health Canada.
November 1, 2002... 2002 NOV 1 - (NewsRx.com & NewsRx.net) -- Generex Biotechnology Corporation (GNBT), a leader in the area of buccal drug delivery, announced that it has filed an investigational new drug (IND) for buccal fentanyl with Health Canada. The...

Vitamin A supplements improve infant nutrition, but not infection risk.
November 1, 2002... 2002 NOV 1 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Vitamin A supplements for pregnant HIV+ women produce mixed results, researchers say. "Vitamin A is essential for immunity and growth," explained Newton...

Positive results reported from phase I/II study with Intranasal Ketamine.
November 1, 2002... 2002 NOV 1 - (NewsRx.com & NewsRx.net) -- Innovative Drug Delivery Systems, Inc., (IDDS) announces positive results from a phase I/II clinical trial that assessed the safety and efficacy of its proprietary formulation of Intranasal Ketamine for...

Eligard 22.5 mg launched as palliative treatment for advanced prostate cancer.
November 1, 2002... 2002 NOV 1 - (NewsRx.com & NewsRx.net) -- Atrix Laboratories, Inc., (ATRX) announced the United States launch of Eligard 22.5 mg (leuprolide acetate suspension for injection), a new proprietary product for the palliative treatment of advanced...

Switching drugs from prescription to OTC raises concerns.
November 1, 2002... 2002 NOV 1 - (NewsRx.com & NewsRx.net) -- It sounds like an easy decision: lift prescription restrictions on some widely used drugs so people can buy what they need without a note from their doctor. But making that change turns out to be a...

Initial accrual complete in HuMax-CD4 phase II study.
November 1, 2002... 2002 NOV 1 - (NewsRx.com & NewsRx.net) -- Genmab A/S announced that the last patient in the initial stage of the HuMax-CD4 phase II trial for patients with active RA has completed the last treatment in the study. Genmab expects to release...

Seroquel effective across full spectrum of schizophrenia symptoms.
November 1, 2002... 2002 NOV 1 - (NewsRx.com & NewsRx.net) -- New data from two important studies revealed for the first time further reinforce the position of the atypical antipsychotic, Seroquel (quetiapine) as a first choice therapy for schizophrenia. ...

U.S. FDA issues approvable letter for aripiprazole.
November 1, 2002... 2002 NOV 1 - (NewsRx.com & NewsRx.net) -- Bristol-Myers Squibb Co. (BMY) and Otsuka Pharmaceutical Co., Ltd., have received an approvable letter from the U.S. Food and Drug Administration (FDA) for aripiprazole (proposed trade name: Abilify...

Phase I vaccine trial yields positive results.
November 1, 2002... 2002 NOV 1 - (NewsRx.com & NewsRx.net) -- Acambis plc has completed a phase I trial of its smallpox vaccine, ACAM1000. The trial tested the safety, tolerability, and immunogenicity of ACAM1000 and Dryvax, the smallpox vaccine that was...

OTC sales of quitting aids up, effectiveness down.
November 1, 2002... 2002 NOV 1 - (NewsRx.com & NewsRx.net) -- Cancer researchers at the University of California, San Diego (UCSD) School of Medicine report in the Journal of the American Medical Association that nicotine replacement therapies (NRT) such as the...

Phase I study of Veronate initiated in premature infants.
November 1, 2002... 2002 NOV 1 - (NewsRx.com & NewsRx.net) -- Inhibitex, Inc., a biopharmaceutical company focused on the prevention and treatment of staphylococcal (staph) and other bacterial infections, announced the start of a phase I clinical trial of its lead...

High-dose antibiotics can prevent etoposide-related infections.
November 1, 2002... 2002 NOV 1 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Potent antibiotics can be used to prevent infections after etoposide-based stem cell mobilization, researchers in the United States say. "High-dose...

Efficacy trials will assess prophylactic and therapeutic indications.
November 8, 2002... 2002 NOV 8 - (NewsRx.com & NewsRx.net) -- Antex Biologics, Inc. (ANX) has announced that two phase II trials for its Helivax vaccine against Helicobacter pylori are scheduled to begin next quarter. One trial will assess the preventative...

Study results of antipsychotic drug offer hope for bipolar disorder sufferers.
November 8, 2002... 2002 NOV 8 - (NewsRx.com & NewsRx.net) -- Results from a clinical trial presented for the first time at Europe's largest Conference on Bipolar Disorder, reveal that Seroquel (quetiapine), a medication currently used to treat patients with...

Viral resistance to entry inhibitors limited.
November 8, 2002... 2002 NOV 8 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - HIV entry inhibitors are unlikely to engender drug-resistant viral mutants, researchers in the United States argue. "Two of the fusion inhibitors T-20 and...

Positive results reported from phase III trial of Memantine.
November 8, 2002... 2002 NOV 8 - (NewsRx.com & NewsRx.net) -- Forest Laboratories, Inc., (FRX) announced that in a recently completed 6-month, placebo-controlled study in patients with moderate-to-severe Alzheimer disease, a significant benefit was observed when...

Phase III data confirm Seroquel in combination with mood stabilizer is effective.
November 8, 2002... 2002 NOV 8 - (NewsRx.com & NewsRx.net) -- AstraZeneca announced that data from the first in a series of phase III trials demonstrate that the combination of Seroquel (quetiapine) and mood stabilizer is significantly more effective than mood...

Study shows Levitra offers consistent results for most men.
November 8, 2002... 2002 NOV 8 - (NewsRx.com & NewsRx.net) -- Bayer Corporation reported study results showing that the majority of men with erectile dysfunction (ED) who were taking the oral investigational drug Levitra (vardenafil HCl) reported improved erectile...

Esterom phase II/III clinical trial results released.
November 8, 2002... 2002 NOV 8 - (NewsRx.com & NewsRx.net) -- Entropin, Inc., (ETOP) announced results of its phase II/III clinical study with Esterom solution for treating impaired shoulder function, and outlined plans for developing its novel new chemical...

Phase I clinical trial results reported for antirejection drug.
November 8, 2002... 2002 NOV 8 - (NewsRx.com & NewsRx.net) -- AtheroGenics, Inc. (NASDAQ:AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, announced positive results from a phase I clinical trial that assessed the safety...

Protease inhibitors compared in treatment-naive HIV/AIDS patients.
November 8, 2002... 2002 NOV 8 - (NewsRx.com & NewsRx.net) -- A study presented at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Diego, California, showed that a regimen containing the investigational protease inhibitor...

Anecortave acetate continues to show efficacy in clinical trials.
November 8, 2002... 2002 NOV 8 - (NewsRx.com & NewsRx.net) -- Data from an ongoing study show anecortave acetate, Alcon, Inc.'s, (NYSE:ACL) investigational new drug, continued to demonstrate effectiveness in reducing vision loss in patients with the wet form of...

Additional phase III trials required by FDA for Cellegesic.
November 8, 2002... 2002 NOV 8 - (NewsRx.com & NewsRx.net) -- Cellegy Pharmaceuticals, Inc., (CLGY) announced that the FDA will require the company to conduct an additional phase III clinical trial in order to obtain approval of Cellegesic (nitroglycerin ointment)...

HIV fusion inhibitors featured at ICAAC.
November 8, 2002... 2002 NOV 8 - (NewsRx.com & NewsRx.net) -- Infectious disease specialists and scientists at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), heard new clinical data on a class of antiretrovirals that attacks HIV in a...

ActivX Biosciences announces new vice-president of advanced technology.
November 8, 2002... 2002 NOV 8 - (NewsRx.com & NewsRx.net) -- ActivX Biosciences, Inc., a privately held biotechnology company developing "chemo-proteomics" technologies for drug discovery, announced the promotion of Jonathan Burbaum, PhD, to the newly created...

Margie Nemcik-Cruz named VP of neurology-, pain-focused pharmaceutical company.
November 8, 2002... 2002 NOV 8 - (NewsRx.com & NewsRx.net) -- Amarin Corp., plc, (AMRN) announced the appointment of Margie Nemcik-Cruz as vice president, regulatory affairs of Amarin Pharmaceuticals, Inc., its U.S. drug development and marketing subsidiary. ...

Positive results from a Provigil ADHD study announced.
November 8, 2002... 2002 NOV 8 - (NewsRx.com & NewsRx.net) -- Cephalon, Inc., (CEPH) announced results from an investigational, multicenter clinical study in 248 children between ages 6-13. The results of the study show that Provigil (modafinil) tablets...

FDA streamlining of biopharmaceutical review a welcomed development.
November 8, 2002... 2002 NOV 8 - (NewsRx.com & NewsRx.net) -- In response to the FDA's plan to consolidate reviews of pharmaceutical products, including biologics, at the Center for Drug Evaluation and Research, BIO [Biotechnology Industry Organization] president...

DTI-015 developer completes enrollment of phase I/II trial of the new drug.
November 8, 2002... 2002 NOV 8 - (NewsRx.com & NewsRx.net) -- Direct Therapeutics, Inc., a privately held drug development company, announced that it has concluded patient enrollment and treatment for its multicenter phase I/II study of DTI-015, a new...

Company to challenge FDA delay of manufactured tamoxifen launch.
November 8, 2002... 2002 NOV 8 - (NewsRx.com & NewsRx.net) -- Barr Laboratories, Inc., (BRL) has announced that it disagrees with a letter, received from the U.S. Food and Drug Administration (FDA), which retroactively alters the approval date of Barr's...

Company spins off Liprostin, its anti-inflammatory/cardiovascular drug.
November 8, 2002... 2002 NOV 8 - (NewsRx.com & NewsRx.net) -- Endovasc Ltd., Inc., (ENVC) announced that in accordance with its new business model, the company has established a new subsidiary, Liprostin Development Corp., for its potential blockbuster...

Boehringer, Pfizer to conduct long-term tiotropium study.
November 8, 2002... 2002 NOV 8 - (NewsRx.com & NewsRx.net) -- Boehringer Ingelheim and Pfizer, Inc., announced the launch of a large-scale, 4-year study to evaluate the potential long-term impact of tiotropium (marketed as Spiriva) on lung function in patients...

Spiriva gets recommendation for approval by FDA committee.
November 8, 2002... 2002 NOV 8 - (NewsRx.com & NewsRx.net) -- Boehringer Ingelheim Pharmaceuticals, Inc., said that an Advisory Committee to the U.S. Food and Drug Administration recommended approval of Spiriva (tiotropium bromide inhalation powder) for the...

Data reported from preclinical DACH platinum study in mice.
November 8, 2002... 2002 NOV 8 - (NewsRx.com & NewsRx.net) -- Access Pharmaceuticals, Inc. (AKC) reported data at the 2nd International Symposium on Tumor Targeted Delivery Systems indicating its experimental compound, AP5346, in the B16 murine melanoma model,...

NDA accepted for filing by FDA for extended-regimen oral contraceptive.
November 8, 2002... 2002 NOV 8 - (NewsRx.com & NewsRx.net) -- Barr Laboratories, Inc., (BRL) announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's new drug application (NDA) for its Seasonale extended regimen oral...

Drug delivery firm submits two abbreviated new drug applications to FDA.
November 8, 2002... 2002 NOV 8 - (NewsRx.com & NewsRx.net) -- Atrix Laboratories, Inc., (ATRX) announced that the company has submitted two abbreviated new drug applications (ANDAs) to the U.S. Food and Drug Administration (FDA) for approval of generic...

Collaboration to study controlled release, targeted delivery of oral medicines.
November 8, 2002... 2002 NOV 8 - (NewsRx.com & NewsRx.net) -- Amarin Corporation plc (NASDAQ:AMRN) announced that its Swedish subsidiary, Amarin Development AB, has entered into a research collaboration with CellGate Inc. to assess the feasibility of improving...

Patent issued with broad claims to method of administering insulin.
November 8, 2002... 2002 NOV 8 - (NewsRx.com & NewsRx.net) -- Generex Biotechnology Corporation (GNBT), a leader in the area of buccal drug delivery, announced that it has received a U.S. patent containing broad claims to its method of administering insulin to the...

Vitamin-mediated tumor targeting data confirm enhanced drug uptake.
November 8, 2002... 2002 NOV 8 - (NewsRx.com & NewsRx.net) -- Access Pharmaceuticals, Inc. (AKC) presented at the 2nd International Symposium on Tumor Targeted Delivery Systems in vitro and in vivo data on vitamin targeted polymers. Linking drugs to polymers...

Compounds selectively target zinc finger protein specific to HIV in vitro.
November 8, 2002... 2002 NOV 8 - (NewsRx.com & NewsRx.net) -- Achillion Pharmaceuticals announced the development of a new class of compounds that inhibits a broad spectrum of drug-resistant HIV strains by targeting a novel virus protein. ACH-0100703, a...

Expanding multiresistant HIV population in need of new classes of drugs.
November 8, 2002... 2002 NOV 8 - (NewsRx.com & NewsRx.net) -- Decision Resources, Inc., a leading research and advisory firm focusing on pharmaceutical and healthcare issues, announced that the expanding multiresistant HIV population is in need of new classes of...

European approval of Fosrenol not expected in 2002.
November 8, 2002... 2002 NOV 8 - (NewsRx.com & NewsRx.net) -- AnorMED announced that it has been notified by its licensee, Shire Pharmaceuticals Group, plc, that the first European approval of Fosrenol, a phosphate binder treatment for end stage renal disease...

New data confirm Keppra's place at the forefront of treatment.
November 8, 2002... 2002 NOV 8 - (NewsRx.com & NewsRx.net) -- Data from a new study, presented at the 5th European Congress on Epileptology in Madrid, further demonstrate the favorable safety and tolerability profiles of Keppra (levetiracetam), helping to confirm...

Complete phase IIA data presented for experimental treatment.
November 8, 2002... 2002 NOV 8 - (NewsRx.com & NewsRx.net) -- Both Palatin Technologies Inc. (PTN) and Jacob Rajfer, MD, professor of urology at the University of California, Los Angeles, School of Medicine, presented results of the company's phase IIA clinical...

$4.5M raised in self-underwritten public offering by BioSante.
November 8, 2002... 2002 NOV 8 - (NewsRx.com & NewsRx.net) -- BioSante Pharmaceuticals, Inc., (BISP) announced that it has raised $4,500,000 in a self-underwritten, best efforts public offering under a registration statement filed with the Securities and Exchange...

NIH grant helps initiate discovery program for new anti-HIV agents.
November 8, 2002... 2002 NOV 8 - (NewsRx.com & NewsRx.net) -- Invenux, Inc. announced that the company was awarded an SBIR grant of $100,000 from the U.S. National Institutes of Health to begin a drug-discovery program aimed at producing novel anti-HIV agents. ...

NIH intended for development of oral prophylactic/therapeutic HIV vaccine.
November 8, 2002... 2002 NOV 8 - (NewsRx.com & NewsRx.net) -- BioDelivery Sciences International (BDSI; BDSIW) announced that they have received a 2-year $600,000 National Institutes of Health (NIH) SBIR Grant to develop an oral form of a powerful HIV...

Viral inhibitors found in Chinese medical herbs.
November 8, 2002... 2002 NOV 8 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Some Chinese herbs with traditional medical uses contain agents capable of blocking HIV activity, researchers report. "An increasing portion of patients...

Data demonstrate potent antiviral activity of new anti-HBV agent.
November 8, 2002... 2002 NOV 8 - (NewsRx.com & NewsRx.net) -- An L-nucleoside antiviral agent, administered orally once daily, rapidly produced potent antihepatitis B virus (HBV) activity in patients chronically infected with HBV, reported Beth Israel Deaconess...

FDA approves first 1-day, oral antiviral treatment of cold sores.
November 8, 2002... 2002 NOV 8 - (NewsRx.com & NewsRx.net) -- GlaxoSmithKline announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Valtrex (valacyclovir HCl) caplets for the treatment of cold sores...

Company gets FDA OK to include superiority data on Atacand label.
November 8, 2002... 2002 NOV 8 - (NewsRx.com & NewsRx.net) -- AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has approved the inclusion in labeling of data from a clinical trial program showing that AstraZeneca's angiotensin II receptor...

Miltefosine effective against drug-resistant Trypanosoma cruzi strains.
November 8, 2002... 2002 NOV 8 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Researchers in Brazil have identified an agent with strong activity against drug-resistant strains of the pathogen responsible for Chagas disease. "The...

Halogenated fluoresceins active against resistant Staphylococcus aureus.
November 8, 2002... 2002 NOV 8 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Researchers in the United States have identified a set of compounds that may be effective against methicillin-resistant strains of Staphylococcus aureus (MRSA)....

FDA approves preservative-free flu vaccine for pediatric use.
November 8, 2002... 2002 NOV 8 - (NewsRx.com & NewsRx.net) -- Aventis Pasteur announced the U.S. Food and Drug Administration (FDA) has approved licensure to market Fluzone Preservative-free: Pediatric Dose, Influenza Virus Vaccine. For the first time,...